FDA De Novo Classification Process Guide: Pathway for Novel Medical Devices

What Is the De Novo Pathway?

The De Novo classification process provides a pathway to market for novel medical devices that are low-to-moderate risk but have no predicate device for a 510(k) submission. Before the De Novo pathway existed, such devices would automatically be classified as Class III (high risk) and require the costly and time-intensive PMA process.

When FDA grants a De Novo request, it creates a new device classification with a new product code and regulation number. This classified device then becomes a predicate for future 510(k) submissions by other manufacturers, opening the market for subsequent similar devices.

De Novo vs. 510(k) vs. PMA

The De Novo pathway is increasingly popular for digital health devices, AI/ML-based software, novel diagnostics, and innovative consumer health technologies that don’t fit neatly into existing device classifications.

Eligibility Criteria

A device is eligible for the De Novo pathway if:

• There is no legally marketed predicate device (no device of the same type)
• The device presents low-to-moderate risk to patients and users
• General controls alone, or general and special controls together, can provide reasonable assurance of safety and effectiveness
• The device is not a banned device or a device for which a PMA has been required by regulation

De Novo requests can be submitted directly (“direct De Novo”) or following receipt of a “Not Substantially Equivalent” (NSE) determination on a 510(k) submission. FDA encourages direct De Novo submissions when no predicate is available.

Pre-Submission Meeting

A pre-submission (Pre-Sub) meeting with FDA is strongly recommended before preparing a De Novo request:

• Pathway confirmation: Confirm that De Novo is the appropriate regulatory pathway for your device
• Classification discussion: Discuss the proposed device classification (Class I or II) and risk profile
• Testing expectations: Clarify FDA’s expectations for performance testing, biocompatibility, and clinical evidence
• Special controls: Preliminary discussion of proposed special controls
• Labeling: Review proposed indications for use and labeling elements

Pre-Sub meetings typically occur 75 days after submission of the Pre-Sub package. This investment of time upfront can significantly reduce review cycles and additional information requests during De Novo review.

De Novo Request Contents

A complete De Novo request includes the following sections:

• Device description: Detailed description including technology, materials, components, and principles of operation
• Intended use and indications: Clear statement of intended use, indications for use, and target population
• Risk analysis: Comprehensive risk analysis identifying all known risks and proposed mitigations
• Non-clinical testing: Bench performance testing, biocompatibility, electrical safety, software verification/validation, and sterility (as applicable)
• Clinical evidence: Clinical data or literature review supporting safety and effectiveness (when required)
• Proposed classification: Recommended Class I or Class II classification with justification
• Proposed special controls: Detailed special controls recommended for the new device type
• Labeling: Proposed labeling including instructions for use, warnings, and precautions

Risk-Based Classification

FDA classifies the device based on risk assessment:

• Class I (General Controls): Lowest risk devices where general controls alone provide reasonable assurance of safety and effectiveness. Subject to establishment registration, device listing, and GMP (21 CFR 820 / QMSR).
• Class II (Special Controls): Moderate risk devices requiring special controls in addition to general controls. Special controls may include performance standards, postmarket surveillance, patient registries, or specific labeling requirements.

The majority of De Novo authorizations result in Class II classification with special controls. Class I De Novo authorizations are less common but do occur for very low-risk novel devices.

FDA Review Process and Timeline

The De Novo review follows a structured process:

• Acceptance review (15 days): FDA screens the submission for completeness and accepts or refuses to accept
• Substantive review (150-day goal): Scientific review of all technical and clinical evidence
• Additional information requests: FDA may issue one or more requests for additional information, which stops the review clock
• Decision: FDA grants the De Novo request, declines to grant, or withdraws the submission
• Classification order: Upon granting, FDA publishes a classification order establishing the new device type

In practice, total elapsed time from submission to decision is typically 10–18 months, including time for additional information requests. Well-prepared submissions with Pre-Sub feedback tend to have shorter review times.

Special Controls Development

Developing effective special controls is a critical component of the De Novo request:

• Performance testing: Specific bench and clinical performance standards the device must meet
• Labeling requirements: Mandatory labeling elements including warnings, contraindications, and instructions for use
• Design controls: Specific design requirements beyond general cGMP/QMSR design control requirements
• Postmarket requirements: Ongoing surveillance, adverse event reporting, or clinical follow-up requirements
• Software requirements: For software-based devices, specific cybersecurity, validation, and update requirements

Well-crafted special controls demonstrate your understanding of the device’s risk profile and improve the likelihood of FDA authorization.

Post-Authorization Requirements

After De Novo authorization, you must maintain compliance with:

• Establishment registration and device listing: Register your facility and list the device with FDA
• Quality System Regulation (QMSR): Comply with 21 CFR 820 or the new QMSR (ISO 13485-based) for design, manufacturing, and distribution
• Medical Device Reporting (MDR): Report adverse events, malfunctions, and deaths per 21 CFR 803
• Special controls: Comply with all special controls established in the De Novo classification order
• Labeling: Maintain compliant labeling as specified in the authorization
• UDI: Assign and maintain Unique Device Identification per 21 CFR 830

How Assurentry Can Help

Assurentry provides comprehensive De Novo regulatory support:

• Pathway assessment: Determine whether De Novo, 510(k), or PMA is the right pathway for your device
• Pre-submission strategy: Develop and submit Pre-Sub packages that get clear FDA feedback
• De Novo preparation: Complete De Novo request preparation including risk analysis, testing strategy, and special controls
• Post-authorization: Ongoing compliance support for establishment registration, device listing, MDR, and UDI